Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

ALEMBIC LTD. - 506235 - Board Meeting Outcome for Outcome Of Board Meeting

 The Board of Directors of Alembic Limited at its meeting held today has inter alia: 1. Approved the Audited Financial Results of the Company for the financial year ended 31st March, 2022. 2. Recommended Dividend of Rs. 1.80/- (90%) per Equity Share having face value of Rs. 2 each for the year ended 31st March, 2022, subject to approval of Shareholders at the ensuing AGM. We enclose the following: A. (i) Consolidated Audited Financial Results (ii) Consolidated Statement of Assets and Liabilities (iii) Consolidated Cash Flow Statement B. (i) Standalone Audited Financial Results (ii) Standalone Statement of Assets and Liabilities (iii) Standalone Cash Flow Statement C. Auditor's Report on Consolidated and Standalone Financial Results. We hereby declare that the Statutory Auditors has issued audit report with unmodified opinion on the Financial Results of the Company. The time of commencement of the Board Meeting was 4:00 p.m. and the time of conclusion was 5:10 p.m.
05-05-2022
Bigul

Annual report for Alembic Ltd. for FY-2022
05-05-2022

Alembic arm receives final USFDA approval for generic fever blisters drug

 Alembic Pharmaceuticals on Wednesday said its wholly-owned arm Aleor Dermaceuticals has received final approval from the US health regulator for its generic Docosanol cream indicated for cold sore/fever blisters on the face or lips. The final approval granted by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Docosanol cream, 10 per cent (over the counter), the company said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product Abreva Cream, 10 per cent (OTC) of GlaxoSmithKline Consumer Healthcare, it added. Citing IQVIA data, Alembic said Docosanol cream, 10 per cent (OTC) has an estimated market size of USD 60 million for 12 months ending December 2021. Alembic has received a cumulative total of 166 ANDA approvals (142 final approvals and 24 tentative approvals) from the USFDA, it added.
04-05-2022
Bigul

ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record.
02-05-2022
Bigul

ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the following registered shareholder(s) and/or legal heir(s) of the registered shareholder(s) on 2nd May, 2022: We request you to kindly take the same on record.
02-05-2022
Bigul

ALEMBIC LTD. - 506235 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates and notice for claiming shares from Company's Unclaimed Suspense Account published by the Company on behalf of the registered shareholder(s) and their legal heir(s) in English language newspaper - Business Standard. We request you to kindly take the same on record.
02-05-2022
Bigul

ALEMBIC LTD. - 506235 - Board to consider FY22 results & Dividend on May 05, 2022

 Alembic Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 05, 2022, inter alia, to transact the following business:1. To consider and approve Audited Financial Results of the Company for the quarter and financial year ended March 31, 2022.2. To consider and recommend dividend on Equity Shares, if any, for the financial year ended March 31, 2022.Pursuant to Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the company which was closed from April 01, 2022, Will reopen 48 hours after the declaration of the financial results.
28-04-2022
Bigul

ALEMBIC LTD. - 506235 - Board Meeting Intimation for Board Meeting To Consider Audited Financial Results For The Quarter And Financial Year Ended On 31St March, 2022

 ALEMBIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2022 ,inter alia, to consider and approve With reference to the captioned matter, the Exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Thursday, 5th May, 2022, inter alia, to transact the following business: 1. To consider and approve Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2022. 2. To consider and recommend dividend on Equity Shares, if any, for the financial year ended 31st March, 2022. Pursuant to Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the company which was closed from 1st April, 2022, will re-open 48 hours after the declaration of the financial results. We request you to kindly take the same on record.
28-04-2022
Bigul

ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s): Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company. We request you to kindly take the same on record.
25-04-2022

Alembic arm Aleor Dermaceuticals gets USFDA nod for plaque psoriasis treatment foam

 The approval granted by the US Food Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Clobetasol Propionate foam, 0.05 per cent, Alembic said in a regulatory filing.
25-04-2022
Next Page
Close

Let's Open Free Demat Account